ERBB2 and breast carcinoma: Expert Panel Recommendations: Based on the findings from the BOLERO series [55, 56] and the MIRACLE study [57], everolimus combined with exemestane is recommended as a treatment option for HR‐positive/HER2‐negative advanced breast cancer patients whose conditions have progressed following prior endocrine monotherapy or combination therapy.